Navigation Links
Alexza Pharmaceuticals to Present at the Fourth Annual JMP Securities Healthcare Focus Conference
Date:10/2/2009

MOUNTAIN VIEW, Calif., Oct. 2 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that company management will present a corporate overview during the Fourth Annual JMP Securities Healthcare Focus Conference, being conducted at the New York Palace Hotel in New York. This corporate overview will be webcast live on Tuesday, October 6, 2009 at 10:30 a.m. Eastern Time.

To access the live presentation via the Web, please go to the direct conference link located at www.wsw.com/webcast/jmp9/alxa/ or at the Alexza Investor Relations tab at www.alexza.com.

A replay of the Webcast will be made available approximately 24 hours after the live presentation and the replay will be archived for 14 days.

About Alexza Pharmaceuticals, Inc.

Alexza Pharmaceuticals is a pharmaceutical company focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions. Alexza's technology, the Staccato® system, vaporizes unformulated drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.

AZ-004 (Staccato loxapine) is Alexza's lead program, which is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, and is projecting a New Drug Application submission in early 2010.

Alexza has completed an
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Alexza Announces Preliminary Results from its AZ-104 (Staccato(R) Loxapine) Phase 2b Trial in Patients with Migraine Headache
2. Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status
3. Endo Pharmaceuticals and Alexza Pharmaceuticals Conclude Research Collaboration
4. Alexza Initiates AZ-104 (Staccato(R) Loxapine) Phase 2b Clinical Trial in Patients With Migraine Headaches
5. Alexzas AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial
6. Alexzas AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients
7. Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
8. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
9. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
10. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
11. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 Abaxis, Inc. (NasdaqGS: ABAX ... systems, today reported financial results for the second fiscal ... overview: , Revenues of $53.9 million, up 18% ... of $0.24, up 33% over last year,s comparable quarter. ... Abaxis Veterinary Reference Laboratories (AVRL) of $3.5 million, up ...
(Date:10/22/2014)... Mass. , Oct. 22, 2014 InVivo ... Cambridge, MA is revolutionizing spinal cord injury ... has been shown to outperform in tissue regrowth in ... the scaffold.  Made from an FDA approved polymer, the ... making it harmless to the human body. NVIV has ...
(Date:10/22/2014)... AUSTIN, Texas , Oct. 22, 2014 /PRNewswire/ ... they have entered into a license and collaboration ... target cancers. PhosImmune possesses technology for ... surfaces of tumor cells in association with HLA ... proteins that play a role in malignancy, are ...
Breaking Medicine Technology:Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 5Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 6Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 7Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 8Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 9Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 10Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 11Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 12Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 13Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 14InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 2InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 3Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2
... April 4, 2011 CarePoint Partners ... Association Annual Conference in Orlando, Florida that it ... infusion therapies including antibiotics, IVIG, nutrition, the associated ... with locations in North Miami and Tampa. This ...
... (Nasdaq: VVUS ) today announced long-term data that ... years showed reductions in blood pressure and the use of ... significant reductions in weight loss as compared to those in ... data – additional results from the SEQUEL study – were ...
Cached Medicine Technology:CarePoint Partners Expands Florida Footprint With Acquisition of Infusion Technologies 2Weight Loss With QNEXA® Over Two Years Provides Patients With Substantial Cardiovascular Benefits 2Weight Loss With QNEXA® Over Two Years Provides Patients With Substantial Cardiovascular Benefits 3
(Date:10/22/2014)... TUESDAY, Oct. 21, 2014 (HealthDay News) -- Measures taken ... plantation in Ebola-ravaged Liberia may have limited the spread ... researchers report. The Firestone Natural Rubber Co. provides ... and residents of nearby densely populated communities. Between ... and suspected Ebola cases among those 80,000 people. That ...
(Date:10/20/2014)... 2014 The newly updated Worldwide Medical ... thousands of facts, figures and forecasts on the global ... sector forecast categories the Worldwide Medical Market Forecasts ... national views on the worldwide medical market to reveal ... gives you data for 2010-2019, covering each country market ...
(Date:10/20/2014)... 20, 2014 The Advocator Group, ... at the American Foundation for Suicide Prevention’s (AFSP) Out ... is a not-for-profit organization that hosts hundreds of community ... these events are used to help understand and prevent ... personal relationships as well. , The Advocator Group ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 T.E.N., ... relationship-marketing firm, announced today that William H. Murray, ... the 2014 ISE® Luminary Leadership Award winner. Presented ... achievements of an outstanding leader and industry practitioner ... contributions in advancing the information security industry. , ...
(Date:10/20/2014)... Los Angeles, CA (PRWEB) October 20, 2014 ... embodies fitness expertise, nutritional coaching, corporate wellness programming, authorship, ... MS, CPT, is excited to announce the release of ... , After many years of coaching thousands of ... pioneering nutrition tracking app that does not require calorie ...
Breaking Medicine News(10 mins):Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 2Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4Health News:JZ Fitness Nutrition App Launches on iTunes 2Health News:JZ Fitness Nutrition App Launches on iTunes 3
... of sexual activity among teens may relate to the ... their childhood, according to a new study released by ... tracking children from age six to eighteen, researchers found ... for adults in television and movies, the earlier they ...
... May 4 Gene Network Sciences, Inc. (GNS) ... Patent No. 7,512,497, entitled "Systems and Methods for ... model learning and simulation platform, REFS(TM) (Reverse Engineering ... in several collaborations with pharmaceutical and biotechnology companies ...
... AMES, Iowa, May 4 Advanced Analytical, based in Ames, ... instrument platform, the DNA PROfiler(TM) system. This ... producing a genetic fingerprint or PROfile. The generated fingerprint ... used for either genus species or strain typing and tracking.Because ...
... May Help Arthritis Sufferers Manage Inflammation and Stiffness ... American adults currently suffer from arthritis - and as ... May has been deemed National Arthritis Month to ... manage associated symptoms. For many with arthritis, one step ...
... in place with GE HealthcareNOIDA, India, May 4 ... announced today that its subsidiary in the United ... Drug Administration (FDA) approval for the Company,s Abbreviated ... The product is found to be bioequivalent and ...
... finds hospital volume to be a useful, albeit imperfect, ... show a quantifiable and statistically significant inverse association between ... studies often fail to show such an association, leading ... imperfect proxy for healthcare quality. , For years, a ...
Cached Medicine News:Health News:Children who view adult-targeted TV may become sexually active earlier in life 2Health News:Gene Network Sciences Awarded Patent Covering REFS(TM) Platform 2Health News:Advanced Analytical Reveals New Platform for Rapid Genotypic Identification of Microorganisms at ASM 2009 2Health News:Experts Recommend Cherries For Pain Relief From Arthritis 2Health News:Experts Recommend Cherries For Pain Relief From Arthritis 3Health News:DRAXIMAGE(R)'s generic Sestamibi Approved for launch in USA 2Health News:DRAXIMAGE(R)'s generic Sestamibi Approved for launch in USA 3Health News:Hospital volume inconsistent predictor of quality care 2
The ZEPHIR Anterior Cervical Plate System is the lowest profile plate clinically available....
... 16 is Philips premium 16-slice CT scanner. ... to automatically delivering high quality, advanced results, the ... a platform that has been the most popular ... comprehensive organ assessment literally within seconds, and with ...
... The PLIF instrument set consists ... conjunction with nerve root protectors, for ... rectangular allograft bone blocks of the ... proper channel preparation which is important ...
... Dilation Port enables the surgeon to perform ... approach using step dilation. Using a series ... aside, creating space for a custom-sized working ... surgeon to operate with a traditional surgical ...
Medicine Products: